The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -29.60 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M 1.10 — flag raised, worth a closer lookWatch
- Earnings quality 61/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Gossamer Bio, Inc. reports it. History and quarterly detail are in the app.
- US License$90.7M
- Revenue from contracts with collaborators$48.5M
- Revenue from PAH research and development service performance obligation satisfied during reporting period$42.3M
- Revenue from PAH research and development costs subject to reimbursement$16.0M
- Revenue from PH-ILD research and development costs subject to reimbursement$13.6M
Leadership changes
From Gossamer Bio, Inc.'s own filings, the day they're filed.
- Skye Drynan · director · appointmenteff. 2024-03-11
- Kristina Burow · Directors · departureeff. 2023-09-06
- John Quisel · director · appointment
Latest filings
- 8-K · Company announcement2026-09-03
- 8-K · Company announcement2026-08-26
- 8-K · Company announcement2026-08-21
- 8-K · Company announcement2026-08-13
- 10-Q · Quarterly report2026-08-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Gossamer Bio, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Gossamer Bio, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.